MRS4738
MRS4738 is a human P2Y14-targeted inhibitor with an IC50 of 3.11 nM. MRS4738 suppresses inflammatory responses of pulmonary neutrophils and lymphocytes, reduces airway eosinophil accumulation, and alleviates mechanical hyperalgesia. MRS4738 can be applied to the research on the mechanisms of diseases associated with pulmonary inflammation, neuropathic pain and asthma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2801625-42-1
- 分子式: C30H24F3NO2
- 分子量:487.51
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
P2Y Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
hP2Y14R 3.11 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
11 μM
Compound: 15
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 35113556] |
体外実験
MRS4738 potently inhibits human P2Y14 receptor binding with an IC50 of 3.11 nM[1].
MRS4738 potently inhibits fluorescent antagonist binding to hP2Y14R-CHO cells with an IC50 of 3.11 nM[2].
MRS4738 inhibits fluorescent antagonist binding to mP2Y14R-HEK293 cells with an IC50 of 33.9 nM, showing lower affinity for mouse P2Y14R than human P2Y14R[2].
MRS4738 binds to the σ2 receptor with a Ki of 0.71 μM and shows minimal other off-target receptor binding[2].
MRS4738 (>30 μM; 24 h, 120 min) is stable in simulated gastric fluid, does not inhibit major CYP isoforms or hERG activity, and has moderate plasma and microsomal stability in mouse, rat, and human systems[2].
MRS4738 potently inhibits fluorescent antagonist binding to hP2Y14R-expressing CHO cells with an IC50 of 3.11 nM, and inhibits mP2Y14R binding with an IC50 of 33.9 nM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 6-12 weeks of age)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; daily; 6 days
-
Result:Significantly reduced total leukocyte counts (P < 0.001) in BALF.
Significantly reduced neutrophil counts (P < 0.05) in BALF.
Significantly reduced macrophage counts (P < 0.05) in BALF.
Significantly reduced lymphocyte counts (P < 0.001) in BALF.
Showed no significant differences in BALF concentrations of TNF-α, IL-1α, IL-1β, IFN-γ, IL-6, and CXCL1 compared to vehicle-treated mice.
化学情報
-
CAS 番号 2801625-42-1
-
分子量 487.51
-
分子式 C30H24F3NO2
-
SMILES
OC(C1=CC2=CC(C3=CC=C(C=C3)C(F)(F)F)=CC=C2C(C4=CC=C([C@@H]5[C@@H]6C[C@@H](NC6)C5)C=C4)=C1)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Whitehead GS, et al. Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice. ACS pharmacology & translational science. 2022 Oct 14;5(10):973-984. [Content Brief]
[2]. Wen Z, et al. Bridged Piperidine Analogues of a High Affinity Naphthalene-Based P2YR Antagonist. Journal of medicinal chemistry. 2022 Feb 24;65(4):3434-3459. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
MRS4738 関連分類
HY-143890 関連分類
Powered by Bioz